OneStat.com Web Analytics
PHP Developer

insmed

Proprietary Protein Platform

IPLEX® is a complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its predominant binding protein IGFBP-3 (rhIGFBP-3). The drug was approved in the United States in December 2005 for the treatment of children with growth failure due to severe primary IGF-I deficiency, and is currently being supplied to a limited number of patients with Amyotrophic Lateral Sclerosis (ALS), or Lou Gehrig's disease, while supplies are available. Insmed also provides support for the development of IPLEX in Retinopathy of Prematurity (ROP).

Press Releases

    • Jan. 20, 2012
      Insmed Incorporated Provides Corporate Update Read More
    • Nov. 14, 2011
      Insmed to Present at Lazard Capital Markets 8th Annual Healthcare Conference Read More
  • Insmed Stock Price